Hormonal therapies and gynaecological cancers.

Abstract

Hormonal therapy has an established place in the management of women with gynaecological malignancies, including first-line therapy for recurrent receptor-positive endometrial cancer and low-grade stromal sarcoma. There is no place for adjuvant hormonal treatment of these cancers after primary surgery. Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases. Response rates to tamoxifen in advanced/recurrent ovarian cancers approximates 10%. To the authors' knowledge, no studies that reasonably compare different progestagens, different routes of therapy, different doses and different hormonal preparations have been published.

• Authors: Andrea Garrett, Michael A Quinn
• Journal: Best practice & research. Clinical obstetrics & gynaecology (Best Pract Res Clin Obstet Gynaecol) Vol. 22 Issue 2 Pg. 407-21 (Apr 2008) ISSN: 1521-6934 [Print] Netherlands
• PMID: 17884734 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Hormonal
• Aromatase Inhibitors
• Progestins
• Tamoxifen

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Aromatase Inhibitors (therapeutic use)
• Endometrial Neoplasms (drug therapy)
• Estrogen Replacement Therapy
• Female
• Genital Neoplasms, Female (drug therapy)
• Humans
• Ovarian Neoplasms (drug therapy)
• Progestins (therapeutic use)
• Sarcoma, Endometrial Stromal (drug therapy)
• Tamoxifen (therapeutic use)